Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H19N3O |
Molecular Weight | 281.3523 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(O)=CC=C3
InChI
InChIKey=MRBDMNSDAVCSSF-UHFFFAOYSA-N
InChI=1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)
Molecular Formula | C17H19N3O |
Molecular Weight | 281.3523 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00692 | https://www.drugs.com/pro/phentolamine.html | http://reference.medscape.com/drug/regitine-oraverse-phentolamine-342392 | https://www.ncbi.nlm.nih.gov/pubmed/26180030
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00692 | https://www.drugs.com/pro/phentolamine.html | http://reference.medscape.com/drug/regitine-oraverse-phentolamine-342392 | https://www.ncbi.nlm.nih.gov/pubmed/26180030
Phentolamine (trade name Regitine) is a reversible nonselective α-adrenergic antagonist used for the control of hypertensive emergencies, most notably due to pheochromocytoma. Phentolamine produces its therapeutic actions by competitively blocking alpha-adrenergic receptors (primarily excitatory responses of smooth muscle and exocrine glands), leading to a muscle relaxation and a widening of the blood vessels. This widening of the blood vessels results in a lowering of blood pressure. The action of phentolamine on the alpha-adrenergic receptors is relatively transient and the blocking effect is incomplete. The drug is more effective in antagonizing responses to circulating epinephrine and/or norepinephrine than in antagonizing responses to mediator released at the adrenergic nerve ending. Phentolamine also stimulates β-adrenergic receptors and produces a positive inotropic and chronotropic effect on the heart and increases cardiac output. Phentolamine is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine is also indicated for the diagnosis of pheochromocytoma by the Phentolamine blocking test. Acute and prolonged hypotensive episodes, tachycardia, and cardiac arrhythmias have been reported. In addition, weakness, dizziness, flushing, orthostatic hypotension, nasal stuffiness, nausea, vomiting, and diarrhea may occur.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6124636 |
3.7 nM [Kd] | ||
Target ID: CHEMBL2094251 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2886664 |
16.6 nM [Kd] | ||
Target ID: CHEMBL2095158 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6330361 |
5.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | REGITINE Approved UsePhentolamine Mesylate for Injection is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine Mesylate for Injection is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine Mesylate for Injection is also indicated for the diagnosis of pheochromocytoma by the phentolamine blocking test. Launch Date-5.6557437E11 |
|||
Primary | REGITINE Approved UsePhentolamine Mesylate for Injection is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine Mesylate for Injection is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine Mesylate for Injection is also indicated for the diagnosis of pheochromocytoma by the phentolamine blocking test. Launch Date-5.6557437E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
67.05 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24452521 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENTOLAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
197.59 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24452521 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENTOLAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.32 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24452521 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENTOLAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
80 mg 10 times / month multiple, oral Highest studied dose Dose: 80 mg, 10 times / month Route: oral Route: multiple Dose: 80 mg, 10 times / month Sources: Page: p.268 |
unhealthy, 26–83 n = 691 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 26–83 Sex: M Population Size: 691 Sources: Page: p.268 |
Disc. AE: Rhinitis, Vomiting... AEs leading to discontinuation/dose reduction: Rhinitis Sources: Page: p.268Vomiting Nausea Diarrhea Headache Dizziness Tachycardia |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Disc. AE: Dyspnea, Tachycardia... AEs leading to discontinuation/dose reduction: Dyspnea (0.84%) Sources: Page: S51Tachycardia (0.84%) Epistaxis (0.84%) Cephalgia (0.84%) Flushing (serious, 0.84%) Chest pain (serious, 0.84%) Shortness of breath (serious, 0.84%) Tachycardia (serious, 0.84%) |
5 mg single, intravenous|intramuscular Recommended Dose: 5 mg Route: intravenous|intramuscular Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Condition: Pheochromocytoma Sources: |
Disc. AE: Myocardial infarction, Cerebrovascular spasm... AEs leading to discontinuation/dose reduction: Myocardial infarction Sources: Cerebrovascular spasm Cerebral vascular occlusion Hypotension |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Diarrhea | Disc. AE | 80 mg 10 times / month multiple, oral Highest studied dose Dose: 80 mg, 10 times / month Route: oral Route: multiple Dose: 80 mg, 10 times / month Sources: Page: p.268 |
unhealthy, 26–83 n = 691 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 26–83 Sex: M Population Size: 691 Sources: Page: p.268 |
Dizziness | Disc. AE | 80 mg 10 times / month multiple, oral Highest studied dose Dose: 80 mg, 10 times / month Route: oral Route: multiple Dose: 80 mg, 10 times / month Sources: Page: p.268 |
unhealthy, 26–83 n = 691 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 26–83 Sex: M Population Size: 691 Sources: Page: p.268 |
Headache | Disc. AE | 80 mg 10 times / month multiple, oral Highest studied dose Dose: 80 mg, 10 times / month Route: oral Route: multiple Dose: 80 mg, 10 times / month Sources: Page: p.268 |
unhealthy, 26–83 n = 691 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 26–83 Sex: M Population Size: 691 Sources: Page: p.268 |
Nausea | Disc. AE | 80 mg 10 times / month multiple, oral Highest studied dose Dose: 80 mg, 10 times / month Route: oral Route: multiple Dose: 80 mg, 10 times / month Sources: Page: p.268 |
unhealthy, 26–83 n = 691 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 26–83 Sex: M Population Size: 691 Sources: Page: p.268 |
Rhinitis | Disc. AE | 80 mg 10 times / month multiple, oral Highest studied dose Dose: 80 mg, 10 times / month Route: oral Route: multiple Dose: 80 mg, 10 times / month Sources: Page: p.268 |
unhealthy, 26–83 n = 691 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 26–83 Sex: M Population Size: 691 Sources: Page: p.268 |
Tachycardia | Disc. AE | 80 mg 10 times / month multiple, oral Highest studied dose Dose: 80 mg, 10 times / month Route: oral Route: multiple Dose: 80 mg, 10 times / month Sources: Page: p.268 |
unhealthy, 26–83 n = 691 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 26–83 Sex: M Population Size: 691 Sources: Page: p.268 |
Vomiting | Disc. AE | 80 mg 10 times / month multiple, oral Highest studied dose Dose: 80 mg, 10 times / month Route: oral Route: multiple Dose: 80 mg, 10 times / month Sources: Page: p.268 |
unhealthy, 26–83 n = 691 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 26–83 Sex: M Population Size: 691 Sources: Page: p.268 |
Cephalgia | 0.84% Disc. AE |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Dyspnea | 0.84% Disc. AE |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Epistaxis | 0.84% Disc. AE |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Tachycardia | 0.84% Disc. AE |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Chest pain | serious, 0.84% Disc. AE |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Flushing | serious, 0.84% Disc. AE |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Shortness of breath | serious, 0.84% Disc. AE |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Tachycardia | serious, 0.84% Disc. AE |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Cerebral vascular occlusion | Disc. AE | 5 mg single, intravenous|intramuscular Recommended Dose: 5 mg Route: intravenous|intramuscular Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Condition: Pheochromocytoma Sources: |
Cerebrovascular spasm | Disc. AE | 5 mg single, intravenous|intramuscular Recommended Dose: 5 mg Route: intravenous|intramuscular Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Condition: Pheochromocytoma Sources: |
Hypotension | Disc. AE | 5 mg single, intravenous|intramuscular Recommended Dose: 5 mg Route: intravenous|intramuscular Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Condition: Pheochromocytoma Sources: |
Myocardial infarction | Disc. AE | 5 mg single, intravenous|intramuscular Recommended Dose: 5 mg Route: intravenous|intramuscular Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Condition: Pheochromocytoma Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Positive phentolamine test in hypertension induced by a nasal decongestant. | 1969 Apr 17 |
|
Use of phentolamine in acute myocardial infarction associated with hypertension and left ventricular failure. | 1973 Apr |
|
Effects of phentolamine, dihydroergocristine and isoxsuprine on the blood pressure and heart rate in normotensive, hypotensive and hypertensive rats. | 1975 |
|
[Effect of several neuroleptic, adreno-, sympatho- and cholinolytic substances on the development of experimental cerebral edema induced by nicotine]. | 1977 May-Jun |
|
A study of the sympathomimetic action of guanethidine on the isolated anococcygeus muscle of the rat. | 1978 Feb |
|
Oral therapy with phentolamine in chronic congestive heart failure. | 1979 Apr |
|
Electrophysiologic properties of hydralazine in man. | 1980 Sep |
|
Noninvasive assessment of load reduction in chronic congestive heart failure patients. | 1981 Aug |
|
Mediation of renin release in essential hypertension by alpha-adrenoreceptors. | 1981 Nov-Dec |
|
Pharmacological characterisation of the alpha-adrenoceptors responsible for a decrease of blood pressure in the nucleus tractus solitarii of the rat. | 1981 Sep |
|
[Acute and chronic cardiac decompensation: is vasodilator therapy useful?]. | 1982 Jan 14 |
|
Alpha-adrenoceptor blockade by phentolamine causes beta-adrenergic vasodilation by increased catecholamine release due to presynaptic alpha-blockade. | 1982 Jan-Feb |
|
Some functional changes in experimentally induced cardiac overload. | 1983 |
|
Contribution of alpha-adrenoceptor activation to the pathogenesis of norepinephrine cardiomyopathy. | 1983 Apr |
|
Role of autonomic nervous system in the pathogenesis of angina pectoris. | 1983 Feb |
|
Ventricular tachycardia induced by clonidine withdrawal. | 1985 Jun |
|
Hypertension after epidural meperidine. | 1985 Nov |
|
Prostaglandins inhibit endogenous pain control mechanisms by blocking transmission at spinal noradrenergic synapses. | 1988 Apr |
|
Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. | 1992 Jul |
|
Effects of adrenergic blockers on central nervous system-mediated hyperglycemia in fed rats. | 1992 May |
|
Presynaptic alpha 2-autoreceptors in brain cortex: alpha 2D in the rat and alpha 2A in the rabbit. | 1993 Jul |
|
Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction. | 1993 May |
|
The involvement of noradrenaline, 5-hydroxytryptamine and acetylcholine in imipramine-induced seizures in mice. | 1993 Oct 15 |
|
Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections. | 1994 |
|
Reasons for high drop-out rate with self-injection therapy for impotence. | 1994 Sep |
|
Contribution of peripheral alpha 1A-adrenoceptors to pain induced by formalin or by alpha-methyl-5-hydroxytryptamine plus noradrenaline. | 1996 Apr 22 |
|
Cocaine-associated myocardial infarction. | 1996 Aug |
|
Neural mechanism of pressor action of nitric oxide synthase inhibitor in anesthetized monkeys. | 1996 Sep |
|
Progressive treatment of erectile dysfunction with intracorporeal injections of different combinations of vasoactive agents. | 1999 Feb |
|
Pretreatment with alpha-adrenergic blockers for prevention of radial artery spasm. | 2002 Oct |
|
Technical aspects of harvesting the radial artery with the harmonic scalpel. | 2003 |
|
Activation of alpha(1)-adrenergic receptors potentiates the nephrotoxicity of ethylene dibromide. | 2003 Apr 22 |
|
Enhancement of PAI-1 mRNA in cardiovascular cells after kainate injection is mediated through the sympathetic nervous system. | 2005 May |
|
Evaluation and management of the patient who has cocaine-associated chest pain. | 2006 Feb |
|
Limited clinical value of bacterial cocaine esterase in cocaine toxicity. | 2010 May |
|
Phentolamine mesylate for accelerating recovery from lip and tongue anesthesia. | 2010 Oct |
|
Insights into the mechanisms mediating hyperglycemic and stressogenic outcomes in rats treated with monocrotophos, an organophosphorus insecticide. | 2012 Mar 29 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/phentolamine.html
Prevention or control of hypertensive episodes in the patient with pheochromo-cytoma. For preoperative reduction of elevated blood pressure, 5 mg of Phentolamine mesylate (1 mg for children) is injected intravenously or intramuscularly 1 or 2 hours before surgery, and repeated if necessary.
During surgery, Phentolamine mesylate (5 mg for adults, 1 mg for children) is administered intravenously as indicated, to help prevent or control paroxysms of hypertension, tachycardia, respiratory depression, convulsions, or other effects of epinephrine intoxication.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26180030
Cancer cell lines, PC-3, DU-145, NCI/ADR-RES, and SKOV3 were used for activity evaluation. Cells were seeded in 96-well plates. After 24 hr,
cells were fixed with 10% trichloroacetic acid (TCA) representing cell population at time zero (T0). After additional incubation of 0.1% DMSO or phentolamine for 48 hr, cells were fixed with 10% TCA and SRB at 0.4% (w/v) in 1% acetic acid was added to stain cells. Unbound SRB was washed out. SRB bound cells were solubilized with 10mM Trizma base.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:51:26 UTC 2023
by
admin
on
Wed Jul 05 22:51:26 UTC 2023
|
Record UNII |
Z468598HBV
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QV03AB36
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
||
|
NCI_THESAURUS |
C29713
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
||
|
NDF-RT |
N0000175553
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
||
|
WHO-ATC |
C04AB01
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
||
|
WHO-ATC |
V03AB36
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
||
|
NDF-RT |
N0000000099
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
||
|
WHO-VATC |
QC04AB01
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000082263
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | |||
|
C62066
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | |||
|
DTXSID4023462
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | |||
|
8153
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | RxNorm | ||
|
5775
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | |||
|
50-60-2
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | |||
|
D010646
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | |||
|
502
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | |||
|
Z468598HBV
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | |||
|
Z468598HBV
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | |||
|
DB00692
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | |||
|
3382
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | |||
|
M8646
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | Merck Index | ||
|
PHENTOLAMINE
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | |||
|
8081
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | |||
|
SUB09785MIG
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | |||
|
22
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | |||
|
CHEMBL597
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | |||
|
2142
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY | |||
|
200-053-1
Created by
admin on Wed Jul 05 22:51:26 UTC 2023 , Edited by admin on Wed Jul 05 22:51:26 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
SHORT-ACTING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||